PDCD1 and neoplasm: Activating immune cells by blocking immune checkpoints and enhancing the anti-tumor response of the immune system are key factors in the therapeutic efficacy of anti-PD-1 immunotherapy, these results suggest that the genes involved in the regulation of immune function may be related to the efficacy of immunotherapy.